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Abstract
Women with hereditary angioedema (HAE) are more likely to be symptomatic that men. Hormonal factors (pub-
erty, contraception, pregnancy,....) play a significant role in the precipitation or worsening of the condition in
women. So, combined contraceptive pills are not indicated and progestogen pill must be preferred. During preg-
nancy, attack rate can increase (38-48% of women). C1Inhibitor concentrate and tranexamic acid can be used dur-
ing pregnancy. Attenuated androgens for long term prophylaxis are effective but side effects appear more often in
female patients. These side effects are dose dependant and can be attenuated by titrating the dose down the low-
est effective level.
Review
Hereditary angioedema (HAE) is inherited in an autoso-
mal dominant manner: consequently both women and
men can be affected. However, published series of her-
editary angioedema report a clear female predominance
(60%) [1,2]. This might be explained by the fact that
women are more likely to be symptomatic than men. In
HAE associated with C1 Inh deficiency, Professor Bork
has shown that women have more clinical episodes than
men (p < 0.02) [2].
Hormonal factors play a significant role in the precipi-
tation or worsening of the condition in women. There
appear to be variation in overall frequency of angioe-
dema symptoms according to the different female life
stages of childhood, puberty, menses, pregnancies and
menopause. Reports have noted a close relationship
between female hormones and angioedema: a mother
and her daughter whose HAE-related symptoms
appeared to be sex hormone dependent [3]. Their first
attack happened around puberty; angioedema worsened
premenstrual and when they took combined oral con-
traceptives. The case of a woman [4] with HAE and
Turner’s syndrome is also very interesting: starting phy-
siological oestrogen replacement at the age of 34 years
old, this woman experienced a worsening both in the
severity and in the frequency of angioedema attacks.
McGlinchey and al [5] described a patient whose symp-
toms of HAE emerged after starting hormone replace-
ment therapy (HRT).
Female sex hormones are known to affect the synth-
esis of many proteins. In the context of bradykinin
mediated angioedema, they act on the kallikrein-kinin
system by increasing synthesis of bradykinin. In ovariec-
tomized rats, studies showed that 17b-estradiol increases
Hageman factor levels by stimulation of gene transcrip-
tion [6-9]. This hormone also increases kininogen and
kallikrein levels [10]. Additionally oestrogens regulate B2
receptor gene expression and function: the vasodepres-
sor response to bradykinin and the B2 receptor mRNA
levels are reduced in ovariectomized rats, and restored
by oestrogen substitution [11]. Progesterone does not
modify Hageman factor levels but seems to raise kallik-
rein cDNA levels [12].
In healthy women taking oral contraception, there is
an increase of fibrinolytic proteins: elevation of plasmin,
factors VII, X, IX and a decrease of plasminogen activa-
tor inhibitor (PAI) [12-14]. These effects appear to be
oestrogen-dependant [13]. The plasma of these women
shows enhanced in vitro fibrinolysis [15]. The contact
system is also affected: Hageman factor, prekallikrein,
kallikrein and high molecular weight kininogen increase
[16-19]. This results in consumption of C1Inh; the
decrease of C1Inh levels correlating with the increase in
Hageman factor [15,16]. Hormone replacement therapy
(HRT) appears to have the same effect, despite lower
oestrogen dose: fibrinolytic proteins (plasminogen and
tissue-type plasminogen activator) rise, PAI decreases
[19-21], Hageman factor, prekallikrein and C3, C4 levels
rise [14,20,21]. Moreover, some studies have shown an
influence of HRT on the bradykinin system: angiotensin
converting enzyme activity decreases whereas bradykinin
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any medium, provided the original work is properly cited.levels increase [22-24]. Visy and al [25] measured serum
sex hormone levels in 44 females with HAE: they found
a positive correlation between the rate of attacks and
oestradiol and progesterone levels. However we don’t
have any information about clinical hormone sensibility
women profile in this study.
It is generally accepted that there are distinct patterns
of HAE in women. We delineate three of them below:
- Oestrogen dependent: these patients reveal the
condition only when they are exposed to the com-
bined contraceptive pill or during pregnancy. They
usually have type III HAE.
- Oestrogen sensitive: the symptoms in these sub-
jects are worsened by taking combined contraceptive
medication or during pregnancy. Any type of HAE
can present in this way.
- Oestrogen-independent: the use of the combined
contraceptive pill or pregnancy does not exacerbate
the symptoms. These individuals represent a minor-
ity of HAE patients.
The relationship between female hormones and
angioedema appeared to be even clearer when the type
III hereditary angioedema was recognised. This HAE
mostly affects women. It was initially described by Bork
et al, Binkley et al, and Martin et al in 2000 as recurrent
angio-oedema without quantitative or functional C1Inh
abnormalities [26-28]. In 2006, Dewald G (et al.) and
Cichon (et al.) identified two mutations in the F12 gene
(gene encoding for Hageman factor) associated with
type III HAE [29,30]. Only 15-20% of the patients suf-
fering from type III HAE had one of these mutations.
The clinical characteristics of type III HAE attacks are
the same as for types I and II, although Bork suggested
that facial swelling occurred considerably more often
[31,32]. In terms of the effect of estrogens, although, AE
attacks occurred preferentially in women taking the OC
pill or during pregnancy [33,34]. Whilst the attacks
appeared to be estrogen-dependent in Binkley’ss e r i e s( i n
which attacks began in the 15 days following starting oral
contraception), they were only estrogen sensitive in the
cases reported by Bork and Martin (estrogen exposure
could induce attacks but after varying periods of time)
[26-28]. We reported that 54.5% of women are estrogen
sensitive and 23% are estrogen dependent, confirming
the potential involvement of estrogen, although the time
between estrogen exposure and onset of the disease
could vary from a few months to eight years [35].
When a physician takes care of women with a HAE,
some issues have to be addressed: the choice of contra-
ception, management of pregnancies and deliveries and
the selection of an effective prophylactic treatment with-
out side effects.
Contraception
Combined contraceptive pills exacerbate symptoms in
63-80% of women [3,36-38]. This method of contracep-
tion is, therefore, contra-indicated in women with her-
editary angioedema. A progestogen pill (mini or full
dose) should be advised in this situation. However, if a
patient is not having problems with the combined pill,
there is no need to stop it. An intra-uterine device is a
good alternative method and is generally very well toler-
ated [36].
Pregnancy
Fertility and the rate of spontaneous abortion are the
same as those found in the normal population. In one
third of cases, pregnancy worsens symptoms, but in
another third the symptoms are improved [36]. Attack
rates increase during pregnancy especially during the
third trimester [39,40]. During pregnancy it is acceptable
to continue background treatment with tranexamic acid
[41]. Danazol is contra-indicated. Treatment of severe
attacks is based on the use of C1Inh concentrate
[40-42].
The management of labour depends on how the preg-
nancy has progressed. If the patient has suffered wor-
sening of the condition with frequent severe episodes,
then labour must be covered with C1 Inh concentrate
(20U/kg by IV infusion). If the disease has been less
severe, there is no need for prophylaxis with C1 Inh
concentrate. However, this should be available in the
delivery room in case it is required. Epidural analgesia is
not only acceptable, but is strongly recommended. The
Caesarean section rate is no higher in these patients
than in the general population.
Lactation
There is no problem with breast-feeding. However, tra-
nexamic acid and danazol should not be taken as they
are secreted in maternal milk. For the same reason icati-
bant should be avoided and only C1Inh concentrate
should be used in the treatment of severe episodes [39].
Menopause
In most patients (55%) the menopause does not alter
the disease. One third is worse while only 13% improve
[36]. Menopausal hormone replacement therapy should
not be given because oestrogen can exacerbate the con-
dition [5].
Breast cancer
The incidence of breast cancer is no higher than in the
rest of the population. Tamoxifen should not be used as
it may worsen symptoms [43].
Women need also specific management for treatment
of HAE.
Bouillet Allergy, Asthma & Clinical Immunology 2010, 6:17
http://www.aacijournal.com/content/6/1/17
Page 2 of 4Short term prophylaxis: three options are available:
attenuated androgens, tranexamic acid or C1Inh con-
centrate. There is no specific problem for the use of the-
ses drugs for short course in female patients. In case of
short term prophylaxis with attenuated androgens, no
virilisation has been observed [44,45].
Acute attack treatment: there is no specific problem
for the use of C1inh concentrate, tranexamic acid, icati-
bant; or ecallantide in female patients.
Long term prophylaxis
Antifibrinolytiques (acid tranexamic) are the first best
choice for HAE women because of good tolerance. The
limits are a moderate efficacy and adverse effects as
nausea, diarrhea and theoretical risk about thromboem-
bolism. These products present no specific effect for
women. Only few women have reported mild dysmenor-
rhea [46,47].
Attenuated androgens are highly effective but are
accompanied by side effects. These side effects appear
more often in female patients. The result of PREHAET
study (presented by Bork) reported a weight gain for
30% of women, virilisation for 6%, menstrual irregulari-
ties for 30%, acne for 7%. Women report also alopecia,
hirsutism, and mammary hypotrophy [48-50]. The side
effects are dose dependant and can be attenuated by
titrating the dose down the lowest effective level
[51-53]. It is important to note that women who take
this treatment may ovulate even if they present men-
strual irregularities or amenorrhea. So, it’s important to
use additional contraceptive method for fertile women
taking attenuated androgens. This treatment must be
stopped in case of pregnancy and lactation.
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